IINN (Inspira Technologies Oxy B.H.N. Ltd) Return on Sales by Gross Profit

The pricing policy of Inspira Technologies Oxy is currently limited by the development stage, while future premium pricing depends on patents and FDA approval. The gross profit margin reflects the dynamics of this process, where -154.70 represents the current metric. This Israeli innovator in emergency medicine has earned the trust of intensive care specialists by creating non-invasive respiratory support systems, ensuring patient safety during therapy.
Comprehensive metric breakdowns and analytics for Inspira Technologies Oxy B.H.N. Ltd (IINN)

For Inspira Technologies Oxy (IINN), a developer of high-tech extracorporeal lung support systems, this metric serves as a key indicator of cost management efficiency in the production of complex medical devices. An analysis of the operating gross margin, calculated as the ratio of the difference between revenue and direct costs to total income, allows investors to assess the scalability of the business model within the intensive care segment and the company's resilience to fluctuations in component costs.